BioAge Labs reported revenue of $2.45M and net income of -$26.65M for the quarter ended Jun 2026, up 1.6% year over year. This income statement covers 12 quarters of results from Sep 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 1.67M | 1.67M | 1.67M | 1.72M | 3.49M | 10.73M | 35.85M | 35.85M | 35.85M | 37.39M | 44.39M | 45.78M |
| Revenue & cost | ||||||||||||
| Revenue | 1.45M | 2.41M | 2.05M | 3.08M | 2.77M | 2.45M | ||||||
| Gross Profit | -4.61M | -4.68M | -14.48M | -13.36M | -3.18M | -11.54M | -10.19M | -15.54M | -10.37M | -14.23M | ||
| Operating items | ||||||||||||
| Research & DevelopmentR&D | 6.53M | 10.08M | 9.32M | 10.47M | 20.02M | 19.23M | 11.11M | 19.84M | 18.51M | 24.50M | 20.41M | 24.36M |
| Selling, General & AdministrativeSG&A | 3.35M | 3.51M | 3.49M | 4.80M | 4.73M | 6.14M | 6.79M | 7.34M | 6.68M | 7.00M | 7.74M | 7.42M |
| Operating ExpensesOpex | 9.89M | 13.60M | 12.81M | 15.27M | 24.75M | 25.36M | 17.90M | 27.18M | 25.19M | 31.50M | 28.15M | 31.78M |
| Operating IncomeOp. Inc | -9.89M | -13.60M | -12.81M | -15.27M | -24.75M | -25.36M | -16.45M | -24.77M | -23.14M | -28.42M | -25.38M | -29.33M |
| EBIT | -9.89M | -13.60M | -12.81M | -15.27M | -24.75M | -25.36M | -16.45M | -24.77M | -23.14M | -28.42M | -25.38M | -29.33M |
| Non-operating items | ||||||||||||
| Non Operating Interest Expenses | 2.40M | 2.56M | 1.22M | 0.44M | 0.39M | 0.32M | 0.26M | 0.20M | 0.15M | 0.09M | 0.04M | 0.00M |
| Interest & Investment IncomeInt & Inv Inc | 0.50M | 0.38M | 1.30M | 2.20M | 2.04M | 4.09M | 3.71M | 3.42M | 3.16M | 2.79M | 3.27M | 3.44M |
| Other Non Operating IncomeOther Non Op Inc. | -0.25M | |||||||||||
| Non Operating IncomeNon Op. Inc. | -4.74M | -7.36M | -0.18M | 1.69M | 1.34M | 4.23M | 3.52M | 3.21M | 2.97M | 2.48M | 3.12M | 3.24M |
| Net income details | ||||||||||||
| EBT | -11.79M | -15.78M | -12.73M | -13.51M | -23.10M | -21.59M | -12.99M | -21.55M | -20.13M | -25.72M | -22.15M | -25.90M |
| Profit After TaxPAT | -14.62M | -20.96M | -12.99M | -13.58M | -23.41M | -21.13M | -12.93M | -21.61M | -20.17M | -25.94M | -22.25M | -26.65M |
| Income from Continuing OperationsIncome (Continuing) | -11.79M | -15.78M | -12.73M | -13.51M | -23.10M | -21.59M | -12.99M | -21.55M | -20.13M | -25.72M | -22.15M | -25.90M |
| Consolidated Net IncomeConsol Net Inc. | -11.79M | -15.78M | -12.73M | -13.51M | -23.10M | -21.59M | -12.99M | -21.55M | -20.13M | -25.72M | -22.15M | -25.90M |
| Income towards Parent CompanyParent Net Inc | -11.79M | -15.78M | -12.73M | -13.51M | -23.10M | -21.59M | -12.99M | -21.55M | -20.13M | -25.72M | -22.15M | -25.90M |
| Net Income towards Common StockholdersNet Income | -11.79M | -15.78M | -12.73M | -13.51M | -23.10M | -21.59M | -12.99M | -21.55M | -20.13M | -25.72M | -22.15M | -25.90M |
| Additional items | ||||||||||||
| EPS (Basic) | -7.05 | -9.43 | -7.61 | -7.90 | -6.61 | -2.01 | -0.36 | -0.60 | -0.56 | -0.72 | -0.52 | -0.58 |
| EPS (Diluted) | -7.05 | -9.43 | -7.61 | -7.90 | -6.61 | -2.01 | -0.36 | -0.60 | -0.56 | -0.72 | -0.52 | -0.58 |
| Shares Outstanding | 1.67M | 1.67M | 1.67M | 1.71M | 3.49M | 10.73M | 35.85M | 35.85M | 35.85M | 35.93M | 42.48M | 44.84M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 1.67M | 1.67M | 1.67M | 1.71M | 3.49M | 10.73M | 35.85M | 35.85M | 35.85M | 35.93M | 42.48M | 44.84M |
| EBITDA | -9.89M | -13.60M | -12.81M | -15.27M | -24.75M | -25.36M | -16.45M | -24.77M | -23.14M | -28.42M | -25.38M | -29.33M |
| Interest ExpensesInt Expense | 2.40M | 2.56M | 1.22M | 0.44M | 0.39M | 0.32M | 0.26M | 0.20M | 0.15M | 0.09M | 0.04M | 0.00M |